Is NBRVF or MCD a better dividend investment in 2026?

NBRVF currently yields 1000000.00% with a 5% 5-year dividend growth rate. MCD yields 2.35% with 8.5% growth. The better choice depends on your goal: NBRVF offers higher current income.

What is the dividend yield difference between NBRVF and MCD?

NBRVF has a forward dividend yield of 1000000.00% ($2.00/share annually). MCD yields 2.35% ($7.26/share annually). The yield gap is 999997.65 percentage points.

Home › Compare › NBRVF vs MCD

NBRVF vs MCD: Dividend Comparison 2026

NBRVF yields 1000000.00% · MCD yields 2.35%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 NBRVF wins by $4.7683925249533696e+36M in total portfolio value

INVESTMENT

TIME HORIZON10 years

NBRVF

● Live price

1000000.00%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.7683925249533696e+36M

Annual income

$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00

Full NBRVF calculator →

MCD

McDonald's Corporation

● Live price

2.35%

Share price

$308.53

Annual div

$7.26

5Y div CAGR

42.3%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$78.5K

Annual income

$26,227.70

Full MCD calculator →

Portfolio growth — NBRVF vs MCD

📍 NBRVF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	NBRVF	MCD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, NBRVF + MCD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

NBRVF pays

MCD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NBRVF

Annual income on $10K today (after 15% tax)

$85,000,000.00/yr

After 10yr DRIP, annual income (after tax)

$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr

MCD

Annual income on $10K today (after 15% tax)

$200.01/yr

After 10yr DRIP, annual income (after tax)

$22,293.55/yr

At 15% tax rate, NBRVF beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NBRVF + MCD for your $10,000?

NBRVF: 50%MCD: 50%

100% MCD50/50100% NBRVF

Portfolio after 10yr

$2.3841962624766848e+36M

Annual income

$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr

Blended yield

99.98%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on MCD right now

NBRVF

No analyst data

Altman Z

-105.0

Piotroski

3/9

MCD

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$351.76

+14.0% upside vs current

Range: $320.00 — $385.00

Altman Z

4.9

Piotroski

5/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NBRVF buys

MCD buys

No recent congressional trades found for NBRVF or MCD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricNBRVFMCD

Forward yield	1000000.00% ✓	2.35%
Annual dividend / share	$2.00	$7.26 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	42.3% ✓
Portfolio after 10y	$4.7683925249533696e+36M	$78.5K ✓
Annual income after 10y	$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00 ✓	$26,227.70
Total dividends collected	$4.7683311610149396e+36M	$58.5K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	Consumer Discretionary

Year-by-year: NBRVF vs MCD ($10,000, DRIP)

Year	NBRVF Portfolio	NBRVF Income/yr	MCD Portfolio	MCD Income/yr	Gap
1← crossover	$100,010,700	$100,000,000.00	$10,815	$334.85	+$100.00M → NBRVF
2	$934,786,450,701	$934,679,439,252.34	$11,826	$491.71	+$934786.44M → NBRVF
3	$8,165,787,108,578,292	$8,164,786,887,076,042.00	$13,123	$730.06	+$8165787108.57M → NBRVF
4	$66,665,884,190,957,650,000	$66,657,146,798,751,470,000.00	$14,853	$1,100.07	+$66665884190957.63M → NBRVF
5	$508,662,171,058,048,100,000,000	$508,590,838,561,963,700,000,000.00	$17,257	$1,690.61	+$508662171058048128.00M → NBRVF
6	$3,627,235,248,428,489,700,000,000,000	$3,626,690,979,905,457,600,000,000,000.00	$20,752	$2,667.01	+$3.62723524842849e+21M → NBRVF
7	$24,173,681,159,150,610,000,000,000,000,000	$24,169,800,017,434,790,000,000,000,000,000.00	$26,103	$4,354.83	+$2.417368115915061e+25M → NBRVF
8	$150,567,402,861,454,640,000,000,000,000,000,000	$150,541,537,022,614,370,000,000,000,000,000,000.00	$34,794	$7,437.78	+$1.5056740286145463e+29M → NBRVF
9	$876,477,100,281,847,600,000,000,000,000,000,000,000	$876,315,993,160,785,800,000,000,000,000,000,000,000.00	$49,926	$13,461.60	+$8.764771002818475e+32M → NBRVF
10	$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000	$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00	$78,550	$26,227.70	+$4.7683925249533696e+36M → NBRVF

NBRVF vs MCD: Complete Analysis 2026

NBRVF — Stock

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

Full NBRVF Calculator →

MCD — Consumer Discretionary

McDonald's Corporation operates and franchises McDonald's restaurants in the United States and internationally. Its restaurants offer hamburgers and cheeseburgers, chicken sandwiches and nuggets, wraps, fries, salads, oatmeal, shakes, desserts, sundaes, soft serve cones, bakery items, soft drinks, coffee, and beverages and other beverages, as well as breakfast menu, including biscuit and bagel sandwiches, breakfast burritos, hotcakes, and other sandwiches. As of December 31, 2021, the company operated 40,031 restaurants. McDonald's Corporation was founded in 1940 and is headquartered in Chicago, Illinois.

Full MCD Calculator →

📬

Get this NBRVF vs MCD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NBRVF vs SCHD NBRVF vs JEPI NBRVF vs O NBRVF vs KO NBRVF vs MAIN NBRVF vs YUM NBRVF vs QSR NBRVF vs SBUX

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.